---
schema_version: "secwatch.filing_event.v1"
accession: "0001753926-23-000046"
form_type: "8-K"
ticker: "LIPO"
cik: "0001347242"
company_name: "LIPELLA PHARMACEUTICALS INC."
filed_at: "2023-01-12T23:59:59+00:00"
generated_at: "2026-06-20T15:55:06.453088+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Lipella reports positive Phase 2a results for LP-10 in hemorrhagic cystitis

## Summary
- All 13 subjects tolerated LP-10 without product-related serious adverse events.
- Dose response observed: decreased hematuria, cystoscopic bleeding/ulceration, improved urinary symptoms.
- Responder analysis: complete response in 3 subjects, partial in 7, no response in 3 subjects.
- LP-10 has Orphan Drug Designation; no FDA-approved treatment exists for hemorrhagic cystitis.
- CEO to present results at Biotech Showcase 2023 on January 11, 2023.

## SEC filing metadata
- accession: 0001753926-23-000046
- form_type: 8-K
- ticker: LIPO
- cik: 0001347242
- company_name: LIPELLA PHARMACEUTICALS INC.
- filed_at: 2023-01-12T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1347242/000175392623000046/0001753926-23-000046-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1347242/000175392623000046/g083352_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001753926-23-000046
- JSON: https://secwatch.observer/filing/0001753926-23-000046.json
- Plain text: https://secwatch.observer/filing/0001753926-23-000046.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.